Cathie Wood's Ark Snaps Back Into Tempus AI With a $12 Million Buy
Cathie Wood's Ark Invest bought a total of 154,521 shares of Tempus AI Inc. (TEM) on Oct. 30, worth about $12.0 million at transaction prices. The purchase was split across two funds: 93,407 shares through the ARK Innovation ETF and 61,114 shares through the ARK Genomic Revolution ETF.
The purchase came right after Ark sold the same stock on the two prior sessions: 7,625 shares on Oct. 29 for $584,151 through the Innovation ETF, and 58,371 shares on Oct. 28. The sequence reads as a short-term rebalance rather than a one-way accumulation.
In the same Oct. 30 batch, Ark sold 17,626 shares of Eli Lilly through the Innovation ETF for $24.21 million, extending a recent pattern of reducing biotech and pharma exposure. Tempus AI and Coinbase were the notable buys disclosed that day.
Tempus AI is a health technology company built around precision medicine. It combines clinical, molecular and imaging data to guide treatment decisions, offers tissue- and blood-based genomic tests, and licenses data from its tests to pharmaceutical companies for drug development.
Tempus AI reports third-quarter results around Nov. 2. Last quarter revenue rose 21.6% to $382.49 million, ahead of the $379.54 million estimate, with an adjusted loss of $0.04 per share against a $0.1517 loss consensus, its sixth straight earnings-per-share beat. Analysts expect about $413 million in third-quarter revenue, roughly 24% growth from a year earlier.
Shares are down about 20.36% over the past month, with a 12-month range of $40.77 to $90.53 and a market capitalization of roughly $12 billion to $13 billion. Ark bought into that pullback just before earnings, a classic buy-the-dip posture for the firm.
H.C. Wainwright raised its Tempus AI price target to $68 from $66 with a Buy rating, while the broader consensus stands at Hold with an average target near $72.37. Revenue has grown about 50% over the last twelve months, though analysts do not expect profitability this year.
Ark's disclosed Tempus AI position stands near $415.8 million, about 5.77% of the relevant portfolio. Against that base, 154,521 shares is a modest top-up, more signal than size.
Tempus AI has a pending $1.5 billion Personalis deal, so the Nov. 2 report must show the core business can carry the acquisition. Ark placed its bet two days before that verdict lands.